divislab glp-1 novo nordisk hikes full-year forecast on drug sales Novo, Lilly buoyed by fast-growing

This article examines the clinical evidence, delivery mechanism challenges, and how genetic predispositions in GLP-1 pathways may inform discussions with healthcare providers about ava

Research evaluating whether the GLP-1 receptor agonist semaglutide is superior to placebo in reducing body weight and knee osteoarthritis pain...

Any GLP-1 agonist can do it, because of how these receptors work in the body

The researchers also did not have access to data on smoking, body-mass index, or blood pressure, so they couldnt make sure that the two groups they were comparingdiabetics with or without semaglutidewere the same according to those variables

Where pharmacy expertise meets modern telehealth.

A new Cleveland Clinic study found those taking GLP-1s were less likely to develop stage IV disease in several cancer types, when compared to patients taking another diabetes medication, DPP-4 inhibitors